Quantitative and functional analyses of CD4+CD25+FoxP3+ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate

British Journal of Haematology

Volumn 153, Issue 1, 2011, Pages 139-143

  Bachy, Emmanuel ^a,b   Bernaud, Janine ^c   Roy, Pascal ^d   Rigal, Dominique ^c   Nicolini, Franck E ^b  

^a UNIVERSITÉ LYON 1   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Chronic myeloid leukaemia; Imatinib mesylate; Immunosuppressive function; Regulatory T cells; Sokal score

Indexed keywords

CD4 ANTIGEN; CYTARABINE; IMATINIB; INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ADULT; BLOOD SAMPLING; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LETTER; LYMPHOCYTE COUNT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 79952584003     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08453.x     Document Type: Letter

References (10)

1. Chen, J., Schmitt, A., Giannopoulos, K., Chen, B., Rojewski, M., Dohner, H., Bunjes, D. & Schmitt, M. (2007) Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. International Journal of Oncology, 31, 1133-1139.
2. Falkenburg, J.H., Wafelman, A.R., Joosten, P., Smit, W.M., van Bergen, C.A., Bongaerts, R., Lurvink, E., van der Hoorn, M., Kluck, P., Landegent, J.E., Kluin-Nelemans, H.C., Fibbe, W.E. & Willemze, R. (1999) Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood, 94, 1201-1208.
3. Galustian, C., Meyer, B., Labarthe, M.C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., Schafer, P., Bartlett, J.B. & Dalgleish, A.G. (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy, 58, 1033-1045.
4. Gregg, R., Smith, C.M., Clark, F.J., Dunnion, D., Khan, N., Chakraverty, R., Nayak, L. & Moss, P.A. (2005) The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clinical and Experimental Immunology, 140, 540-546.
5. Larmonier, N., Janikashvili, N., LaCasse, C.J., Larmonier, C.B., Cantrell, J., Situ, E., Lundeen, T., Bonnotte, B. & Katsanis, E. (2008) Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. Journal of Immunology, 181, 6955-6963.
6. Milpied, P., Renand, A., Bruneau, J., Mendes-da-Cruz, D.A., Jacquelin, S., Asnafi, V., Rubio, M.T., MacIntyre, E., Lepelletier, Y. & Hermine, O. (2009) Neuropilin-1 is not a marker of human Foxp3+ Treg. European Journal of Immunology, 39, 1466-1471.
7. Minnema, M.C., van der Veer, M.S., Aarts, T., Emmelot, M., Mutis, T. & Lokhorst, H.M. (2009) Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia, 23, 605-607.
8. Olivieri, A., Locatelli, F., Zecca, M., Sanna, A., Cimminiello, M., Raimondi, R., Gini, G., Mordini, N., Balduzzi, A., Leoni, P., Gabrielli, A. & Bacigalupo, A. (2009) Imatinib for refractory chronic graft-versus-host-disease with fibrotic features. Blood, 114, 709-718.
9. Rohon, P., Porkka, K. & Mustjoki, S. (2008) Effect of tyrosine kinase inhibitors on regulatory T-cells (Tregs) in patients with Chronic Myeloid Leukemia (CML). Haematologica, 93, 44-45 [Abstract].
10. Zorn, E., Kim, H.T., Lee, S.J., Floyd, B.H., Litsa, D., Arumugarajah, S., Bellucci, R., Alyea, E.P., Antin, J.H., Soiffer, R.J. & Ritz, J. (2005) Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood, 106, 2903-2911.